Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several...

Full description

Bibliographic Details

Published in:	Dermatology Reports
Main Authors:	Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini
Format:	Article
Language:	English
Published:	PAGEPress Publications 2025-07-01
Subjects:	Psoriasis risankizumab erythrodermic psoriasis safety efficacy
Online Access:	https://www.pagepress.org/journals/dr/article/view/10379